Yazar "Kaplan, Muhammed A." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Colorectal Cancer in Patients Aged ?30 Years: 17 Years of Experience
    (Erciyes Univ Sch Medicine, 2019) Ozaydin, Sukru; Atas, Erman; Tanriseven, Mustafa; Kaplan, Muhammed A.; Hartendorp, Patrick; Unlu, Aytekin; Petrone, Patrizio
    Objective: Although its incidence has been increasing, colorectal cancer is rare in young patients. There are conflicting reports on its prognosis in young patients with colorectal cancers. The goal of this study is to investigate the prognostic factors in young patients with colorectal cancer. An observational, population-based, retrospective study. Materials and Methods: The clinicopathological characteristics, treatment approaches, and survival data of patients with colorectal cancers aged 30 years and younger were retrospectively analyzed. Results: A total of 32 patients were identified. Hematochezia and abdominal pain were the major signs of colorectal cancer. Left-sided tumors (rectum 53.1%, and left colon 25%) were found to be more common than right-sided (18.8%) and transverse colon tumors (3.1%). Curative surgery was performed in 81.3% of patients. Histologically, 43.8% of cancers found were poorly differentiated. According to the subtype, 21.9% were signet ring cell, and 25% were mucinous (colloid) tumors. Patients were evaluated as Stage III in 46.9% and Stage IV in 31.3% of cases. The 3-year progression-free survival (PFS) was 38.7%, and the 3-year overall survival (OS) was 53.2%. Stage IV disease and disease without curative surgery were poor prognostic factors, both for the OS and PFS. Conclusion: Prognosis was poor in young patients with colorectal cancer. In this institutional study, an advanced stage, left-sided localization, and poor histological feature were frequently detected. The stage and complete surgery were predictive factors for the long-term survival. In this respect, it is important for physicians to heighten their awareness of the increased incidence of colon cancer in younger patients.
  • [ X ]
    Öğe
    Outcome of 561 non-metastatic triple negative breast cancer patients: Multi-center experience from Turkey
    (Imprimatur Publications, 2014) Budakoglu, Burcin; Altundag, Kadri; Aksoy, Sercan; Kaplan, Muhammed A.; Ozdemir, Nuriye Y.; Berk, Veli; Ozkan, Metin
    Purpose: Triple-negative breast cancers account for 15% of breast carcinomas and, when present as early-stage disease, they are associated with higher rates of recurrence and early distant metastasis risk when compared to hormone receptor positive and human epidermal growth factor receptor (HER-2) positive breast cancers. In this study we aimed to explore the basic clinicopathological characteristics, prognostic factors and recurrence patterns of non-metastatic triple negative breast cancer patients. Methods: In this study 561 non-metastatic triple-negative breast cancer female patients admitted to 8 different cancer centers in Turkey between 2000 and 2010 were retrospectively evaluated through their medical records, to identify the basic clinico-pathological characteristics, prognostic factors and recurrence patterns. Results: The ratio of triple-negative breast cancer was 12%. The median age of patients was 48 years, of whom 311 (55.4%) were premenopausal. The majority had early-stage breast cancer at the time of diagnosis (16.8% stage I, 48.1% stage II, 35.1 % stage III) and the most commonly identified variant was invasive ductal carcinoma (84.1%). Grade II and III tumors were 27.1 and 48.5%, respectively. Adjuvant chemotherapy was administered to 90.5% of women and adjuvant radiotherapy to 41.2%. Median patient follow up was 28 months (range 3-290). During the follow up period 134 (23.8%) patients developed metastatic disease. In most of these cases, metastatic sites were bone, soft tissue, and lung. Factors affecting disease free survival (DFS) and overall survival (OS) were age (both p<0.001), lymph node involvement (both p<0.001), lymphovascular invasion (LVI) (p<0.001 and p=0.004, respectively), tumor stage (both p<0.001), adjuvant administration of anthracycline-based chemotherapy (both <0.001) and type of surgery (not significant for DFS but p=0.05 for OS). Three-year DFS and OS were 72.0 and 93.0%, respectively. Conclusion: Age, lymph node involvement, LVI, stage, and adjuvant chemotherapy were determined as prognostic factors for DFS and OS. The most common recurrence sites were bone, soft tissue and the lung. Further prospective randomised trials are needed to confirm the prognostic and predictive factors identified in this study.